Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma

BACKGROUND: Gemcitabine plus cisplatin (GP) is commonly used to treat lung squamous cell carcinoma (SCC); however, it is not clear which subgroup of lung SCC patients could benefit most from GP treatment. We explored the predictive factors in lung SCC patient cohorts. METHODS: Seventy‐eight lung SCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jia, Zheng, Qiwen, Gao, Emei, Dong, Zhi, Zhao, Jun, An, Tongtong, Wu, Meina, Zhuo, Minglei, Wang, Yuyan, Li, Jianjie, Wang, Shuhang, Yang, Xue, Chen, Hanxiao, Jia, Bo, Wang, Jingjing, Wang, Ziping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792736/
https://www.ncbi.nlm.nih.gov/pubmed/29318765
http://dx.doi.org/10.1111/1759-7714.12581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792736/
https://www.ncbi.nlm.nih.gov/pubmed/29318765
http://dx.doi.org/10.1111/1759-7714.12581

Ejemplares similares